Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Simple item page
dc.contributor.authorJordana B. Cohen
dc.contributor.authorThomas C. Hanff
dc.contributor.authorPreethi William
dc.contributor.authorNancy K. Sweitzer
dc.contributor.authorNelson R. Rosado‐Santander
dc.contributor.authorC. Medina
dc.contributor.authorJuan E. Rodriguez‐Mori
dc.contributor.authorNicolás Renna
dc.contributor.authorTara I. Chang
dc.contributor.authorVicente Corrales‐Medina
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T13:51:31Z
dc.date.available2026-03-22T13:51:31Z
dc.date.issued2021
dc.descriptionCitaciones: 223
dc.identifier.doi10.1016/s2213-2600(20)30558-0
dc.identifier.urihttps://doi.org/10.1016/s2213-2600(20)30558-0
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/43130
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofThe Lancet Respiratory Medicine
dc.sourceUniversity of Pennsylvania
dc.subjectDiscontinuation
dc.subjectMedicine
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectRenin–angiotensin system
dc.subjectOpen label
dc.subject2019-20 coronavirus outbreak
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectProspective cohort study
dc.subjectClinical trial
dc.subjectInternal medicine
dc.titleContinuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
dc.typearticle

Files

Collections

Artículo Científico Publicado